Apparatus and method for inter-network communication
    1.
    发明授权
    Apparatus and method for inter-network communication 失效
    网络间通信的装置和方法

    公开(公告)号:US06205216B1

    公开(公告)日:2001-03-20

    申请号:US08791046

    申请日:1997-01-28

    IPC分类号: H04M700

    摘要: The invention provides an apparatus for transmitting calls generated by a first communication network over a second communication network to a third communication network, the first communication network operating in accordance with a first communication protocol which enables call services, the third communication network operating in accordance with a communication protocol which enables at least one of the call services enabled by the first communication protocol and the second communication network operating according to a second communication protocol different to the first. The apparatus includes means to produce a data message compatible with the second communication protocol indicative of the required service and means to transmit the call and data message over the second communication network to the third communication network, where the data message is read by further apparatus and an appropriate call service established to the third communication network. By providing means to produce a data message compatible with the second protocol to carry the call service information it is possible to establish a call service over a communications network even though that network does not explicitly support the call service.

    摘要翻译: 本发明提供一种用于通过第二通信网络向第三通信网络发送由第一通信网络产生的呼叫的装置,所述第一通信网络根据能够进行呼叫服务的第一通信协议操作,所述第三通信网络根据 通信协议,其使得能够根据与第一通信协议不同的第二通信协议,由第一通信协议和第二通信网络启用的呼叫服务中的至少一个进行操作。 该装置包括产生与指示所需服务的第二通信协议兼容的数据消息的装置,以及通过第二通信网络将呼叫和数据消息发送到第三通信网络的装置,其中数据消息由另外的装置读取, 建立到第三通信网络的适当呼叫服务。 通过提供用于产生与第二协议兼容的数据消息以携带呼叫服务信息的装置,即使该网络没有明确地支持呼叫服务,也可以通过通信网络建立呼叫服务。

    Communication apparatus and method
    2.
    发明授权
    Communication apparatus and method 失效
    通讯装置及方法

    公开(公告)号:US5517564A

    公开(公告)日:1996-05-14

    申请号:US313602

    申请日:1994-09-29

    摘要: Method and apparatus are provided for transmitting calls generated by a first communication network over a second communication network to a third communication network wherein the first communication network operates in accordance with a first communication protocol which enables call services, the third communication network operates in accordance with a communication protocol which enables at least one of the call services enabled by the first communication protocol and the second communication network operates according to a second communication protocol different from the first. The apparatus includes elements to determine whether a call to be routed from the first communication network to the third communication network by means of the second communication network requires a call service to produce a data message compatible with the second communication protocol indicative of the required service and to transmit the call and data message over the second communication network to the third communication network, where the data message is read and an appropriate call service established to the third communication network. By producing a data message compatible with the second protocol to carry the call service information it is possible to establish a call service over a communications network even though that network does not explicitly support the call service.

    摘要翻译: 提供了用于将第一通信网络通过第二通信网络产生的呼叫传送到第三通信网络的方法和装置,其中第一通信网络根据能够进行呼叫服务的第一通信协议进行操作,第三通信网络根据 通信协议,其使得能够由第一通信协议和第二通信网络启用的呼叫服务中的至少一个根据与第一通信协议不同的第二通信协议来操作。 该装置包括用于确定通过第二通信网络从第一通信网络路由到第三通信网络的呼叫是否需要呼叫服务以产生与表示所需服务的第二通信协议兼容的数据消息的元素,以及 以通过第二通信网络将呼叫和数据消息发送到第三通信网络,其中数据消息被读取,并且向第三通信网络建立适当的呼叫服务。 通过产生与第二协议兼容的数据消息来承载呼叫服务信息,即使该网络没有明确地支持呼叫服务,也可以通过通信网络建立呼叫服务。

    Acyl bicyclic derivatives of pyrrol
    3.
    发明申请

    公开(公告)号:US20050176801A1

    公开(公告)日:2005-08-11

    申请号:US10514898

    申请日:2003-05-15

    摘要: The invention relates to anti-viral agents of Formula (I) wherein: RA represents OR1, NR1R2, or R1 wherein R1 and R2 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RB represents C(O)R3 wherein R3 represents aryl or heteroaryl; RC represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; RD represents hydrogen and RE represents hydrogen, OR4 or SR4, or RD and RE together with the carbon atom to which they are attached form a carbonyl group or a thiocarbonyl group; when RE is hydrogen, OR4 or SR4, RG and RH are both hydrogen; when RD and RE together with the carbon atom to which they are attached form a carbonyl group or a thiocarbonyl group, RG represents hydrogen and RH represents hydrogen, OR4 or SR4, or RG and RH together with the carbon atom to which they are attached form a carbonyl group or a thiocarbonyl group; R4 represents hydrogen, C1-6alkyl or aryl; when RD and RE together with the carbon atom to which they are attached form a carbonyl group or a thiocarbonyl group, and RG and RH are both hydrogen or RG and RH together with the carbon atom to which they are attached form a carbonyl group or a thiocarbonyl group, then RF represents O, S, NR5 or CR6R7, otherwise RF represents CR6R7; R5 represents hydrogen, C1-6alkyl, arylalkyl or aryl; R6 and R7 independently represent hydrogen, C1-6alkyl, arylalkyl or heteroarylalkyl; RJ represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and enantiomers thereof; provided that when RA is OR1 then R1 is other than tert-butyl. A process for the preparation of compounds of Formula (I) and methods of using them in HCV treatment are provided.

    Nucleoside compounds in hcv
    4.
    发明申请
    Nucleoside compounds in hcv 审中-公开
    核苷类化合物在hcv

    公开(公告)号:US20050009775A1

    公开(公告)日:2005-01-13

    申请号:US10481081

    申请日:2002-05-15

    CPC分类号: C07H19/10 C07H19/20

    摘要: Protide compounds of formula (I) wherein X represents H, F, N3, NH2, —CN, or —OMe; X1 represents O or NR7; X2 represents O, NH, NR6 or S, or when X3 is O then X2 is absent; X3 is absent, or when X1 is O then X3 represents O; R1 represents hydrogen; optionally substituted C1-6alkyl; optionally substituted aryl; or optionally substituted heteroaryl; R2 represents hydroxy, OCOR6, or OCO2R6; R3 represents H, optionally substituted C1-6alkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl; R4 and R5 are independently selected from hydrogen, optionally substituted C1-6alkyl, optionally substituted aryl, or optionally substituted aralkyl; R6 represents optionally substituted C1-6alkyl or optionally substituted aryl; R7 represents H, optionally substituted C1-6alkyl, or optionally substituted aryl, wherein when R4 and R7 are each alkyl they may be linked to form a 5- or 6-membered ring; B represents (a), (b), (c), or (d) wherein Z represents O or S; R8 represents H, halo, C2-4alkynyl, trifluoromethyl, C1-3alkoxy, hydroxy, methylthio, amino, nitro, or C1-3alkyl wherein the C1-3alkyl may be optionally substituted by hydroxy, halo, amino, or OR10 wherein R10 represents C1-6alkyl optionally substituted by aryl which may itself be optionally substituted; and R9 represents H, halo, hydroxy, OR6, SR6 or NR3R3; are useful in the treatment of viral infection, particularly HCV infection.

    摘要翻译: 保护式(I)的化合物,其中X表示H,F,N 3,NH 2,-CN或-OMe; X 1表示O或NR 7; X 2表示O,NH,NR 6或S,或当X 3为O时,X 2不存在; X 3不存在,或当X 1为O时,X 3表示O; R 1表示氢; 任选取代的C 1-6烷基; 任选取代的芳基; 或任选取代的杂芳基; R 2表示羟基,OCOR 6或OCO 2 R 6; R 3表示H,任选取代的C 1-6烷基,任选取代的芳基,任选取代的杂芳基或任选取代的杂环基; R 4和R 5独立地选自氢,任选取代的C 1-6烷基,任选取代的芳基或任选取代的芳烷基; R 6表示任选取代的C 1-6烷基或任选取代的芳基; R 7表示H,任选取代的C 1-6烷基或任选取代的芳基,其中当R 4和R 7各自为烷基时,它们可以连接形成5-或6-元环; B表示(a),(b),(c)或(d)其中Z表示O或S; R 8表示H,卤素,C 2-4炔基,三氟甲基,C 1-3烷氧基,羟基,甲硫基,氨基,硝基或C 1-3烷基,其中C 1-3烷基可任选被羟基,卤素,氨基或OR 其中R 10表示任选被可以被任选取代的芳基取代的C 1-6烷基; 并且R 9表示H,卤素,羟基,OR 6,SR 6或NR 3 R 3; 可用于治疗病毒感染,特别是HCV感染。

    Acyl dihydro pyrrole derivatives as hcv inhibitors
    6.
    发明申请
    Acyl dihydro pyrrole derivatives as hcv inhibitors 审中-公开
    酰基二氢吡咯衍生物作为hcv抑制剂

    公开(公告)号:US20050009873A1

    公开(公告)日:2005-01-13

    申请号:US10494121

    申请日:2002-10-30

    CPC分类号: C07D417/04

    摘要: Novel anti-viral agents of Formula (I) wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; D represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; E represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.

    摘要翻译: 式(I)的新型抗病毒剂,其中:A表示OR 1,NR 1 R 2或R 1,其中R 1和R 2为氢,C 1-6烷基, 芳基,杂芳基,芳基烷基或杂芳基烷基; 或R 1和R 2与它们所连接的氮原子一起形成5或6元饱和环状基团; B表示C(O)R 3,其中R 3是C 1-6烷基,芳基,杂芳基,芳烷基或杂芳基烷基; D表示C 1-6烷基,芳基,杂芳基或杂环基; E表示OR 1,NR 1 R 2或R 1,其中R 1和R 2是氢,C 1-6烷基,芳基,杂芳基,芳烷基或杂芳基烷基; 或R 1和R 2与它们所连接的氮原子一起形成5或6元饱和环状基团; F表示氢,C 1-6烷基,芳基或杂芳基; 和G表示氢,C 1-6烷基,杂环基烷基,芳基烷基或杂芳基烷基; 并提供其盐和溶剂化物,其制备方法及其在HCV治疗中的使用方法。

    New compounds
    8.
    发明申请
    New compounds 审中-公开
    新化合物

    公开(公告)号:US20060217375A1

    公开(公告)日:2006-09-28

    申请号:US11318126

    申请日:2005-12-22

    CPC分类号: C07D491/10 C07D493/10

    摘要: The present invention relates to compounds of Formula (I): wherein R1, A, Y, n and m are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of orexin-1 receptor-related disorders and orexin-2 receptor-related disorders. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, drug addiction, and sleeping disorders.

    摘要翻译: 本发明涉及式(I)的化合物:其中R 1,A,Y,n和m如本文所述,制备化合物的方法,包含该化合物的药物组合物和使用 预防或治疗食欲肽-1受体相关疾病和食欲肽-2受体相关疾病的化合物和组合物。 这种障碍的实例是肥胖症和相关疾病,例如II型糖尿病,血脂异常和代谢综合征,心血管疾病如动脉粥样硬化性血管疾病,心绞痛,心肌梗死和中风,药物成瘾和睡眠障碍。

    Proppant recovery system
    9.
    发明授权
    Proppant recovery system 失效
    支撑剂回收系统

    公开(公告)号:US07040418B2

    公开(公告)日:2006-05-09

    申请号:US10284125

    申请日:2002-10-30

    IPC分类号: E21B21/06 B09B5/00

    CPC分类号: E21B41/005 E21B21/01

    摘要: An improved method for removing proppant from fluid used in an oil and gas well for reuse in future operations. The proppant is separated from the well fluid and transported to a materials collection tank. A crane then transports the materials collection tank onto a processing boat. On the processing boat, the proppant is vacuumed from the materials collection tank to a hopper. The proppant is then discharged from the hopper into a holding tank for treatment and reuse. In a first alternative embodiment, two hoppers are positioned above each other so that the proppant can be added to the upper hopper and then fed by gravity to the lower hopper. A valving arrangement maintains vacuum within the interior of at least one hopper at all times to provide a continuous vacuum operation. A conduit discharges from the lower hopper into the holding tank.

    摘要翻译: 一种改进的方法,用于从石油和天然气井中使用的流体中除去支撑剂,以供将来的作业再利用。 支撑剂与井液分离并运送到材料收集罐。 然后起重机将物料收集罐运输到加工船上。 在处理船上,将支撑剂从材料收集罐抽真空至料斗。 然后将支撑剂从料斗中排出到储罐中进行处理和再利用。 在第一替代实施例中,两个料斗位于彼此之上,使得支撑剂可以被添加到上料斗中,然后通过重力进料到下料斗。 阀装置始终在至少一个料斗的内部保持真空以提供连续的真空操作。 管道从下料斗排放到储罐中。